Showing 321-330 of 7665 results for "".
- Study: Men With Skin of Color Are More Likely to Die From Melanomahttps://practicaldermatology.com/news/study-men-with-skin-of-color-are-more-likely-to-doe-from-melanoma/2461853/Men with melanoma – and particularly men with skin of color – are more likely to die than women with melanoma, a new study in the Journal of the American Academy of Dermatology shows. "We know that men may be less likely to seek medical care than women, so they can be diagnosed with melanoma at la…
- WCD News: Connect Biopharma's Rademikibart Earns High Marks in ADhttps://practicaldermatology.com/news/wcd-news-connect-biopharmas-rademikibart-earns-high-marks-in-ad/2461851/Four new studies support the efficacy and safety of rademikibart in atopic dermatitis (AD), Connect Biopharma reports. Rademikibart (CBP-201), a next-generation IL-4Rα antibody, achieved all primary and secondary endpoints in a randomized pivotal trial for moderate-to-severe AD in China. This pos…
- MRA's RARE Registry for Acral & Mucosal Melanoma Surpasses 100-Patient Milestonehttps://practicaldermatology.com/news/mras-rare-registry-for-acral-mucosal-melanoma-surpasses-100-patient-milestone/2461850/The Melanoma Research Alliance’s (MRA) RARE Registry for acral and mucosal melanoma has officially surpassed 100 patients, the group reports. The MRA began work in 2020 to launch RARE, a direct-to-patient interactive portal, to accelerate treatment options, support research and ultimately find a c…
- Fecal Transplants Show Promise in Improving Response to Immunotherapy in Melanoma Patientshttps://practicaldermatology.com/news/fecal-transplants-show-promise-in-improving-response-to-immunotherapy-in-melanoma-patients/2461849/Fecal microbiota transplants (FMT) from healthy donors are safe and show promise in improving response to immunotherapy in patients with advanced melanoma, according to research in Nature Medicine. Preliminary research has suggested that the human microbiome may play a role in whether or not a pat…
- Regular Moisturizer Use May Reduce Signs of Aging Skin, Plus More Research from Estée Lauderhttps://practicaldermatology.com/news/regular-moisturizer-use-may-reduce-signs-of-aging-skin-on-the-face-skin-aging-plus-more-wcd-presented-research-from-estee-lauder/2461846/Regular use of moisturizer can mitigate skin aging, according to research presented by The Estée Lauder Companies Inc. at the 25th World Congress of Dermatology in Singapore. In an evaluator-blinded, randomized, 6-month longitudinal study of 160 women, aged 35-65, with dry skin, mild to moderate …
- AD Pipeline Watch: Eblasakimab Monthly Dosing Shows Promise in Phase 2b AD Studyhttps://practicaldermatology.com/news/eblasakimab-monthly-dosing-shows-promise-in-phase-2b-ad-study/2461845/ASLAN Pharmaceuticals’ eblasakimab met the primary endpoint of percent change from baseline in the Eczema Area and Severity Index (EASI) score at week 16 versus placebo in adult patients with moderate-to-severe atopic dermatitis (AD), according to results from the Phase 2b dose-ranging TREK-AD (TRi…
- Novel Peptide T14 May Reflect Age and Photoaging in Human Skinhttps://practicaldermatology.com/news/novel-peptide-t14-may-reflect-age-and-photo-aging-in-human-skin/2461843/A novel peptide ‘T14’ may reflect age and photoaging in human skin, according to a study in Aging. T14 is a 14mer peptide derived from the C-terminus of acetylcholinesterase (AChE). Once cleaved, it is independently bioactive of the parent molecule and enhances calcium influx in different cell typ…
- NY Dermatologist Louise Kaufmann, MD, Wins an International Award for Social Responsibility in Dermatology from L’Oréal and ILDShttps://practicaldermatology.com/news/dr-louise-kaufmann-wins-an-international-awards-for-social-responsibility-in-dermatology-from-loreal-and-ilds/2461842/Louise Kaufmann, MD, a general and cosmetic dermatologist in Great Neck, New York, took home an International Award for Social Responsibility in Dermatology for her efforts to provide access to dermatological care in rural and underserved areas of Jamaica. The awards, spearheaded by L’Oréal in pa…
- Nemolizumab Monotherapy Curbs Itch in Prurigo Nodularis by Week 4https://practicaldermatology.com/news/nemolizumab-monotherapy-curbs-itch-in-prurigo-nodularis-by-week-4/2461840/Nemolizumab monotherapy quickly tames itch in Prurigo Nodularis, according to a late-breaking late-breaking Phase III study presented at the 25th World Congress of Dermatology (WCD) in Singapore. Fully 19.7% of patients treated with nemolizumab monotherapy achieved an itch-free state as early as w…
- MHRA Grants Marketing Authorization for Incyte's Opzelura Cream for Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescentshttps://practicaldermatology.com/news/mhra-grants-marketing-authorization-for-incytes-opzelura-cream-for-non-segmental-vitiligo-with-facial-involvement-in-adults-and-adolescents/2461838/The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing clearance for Incyte’s Opzelura (ruxolitinib) cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. “Today’s MHRA approval is welcome new…